Summit flags going concern doubt as burn rate doubles; BLA accepted but FDA wants OS data

Filed April 30, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 1, 2025 · ~2 min read

Key Changes

• high

  Company disclosed substantial doubt about continuing as going concern, stating cash insufficient for next 12 months despite $598.7M on hand. Operating burn doubled to $122.3M/quarter from $61.2M prior year.

  Risk Factors / MD&A: Liquidity verify on EDGAR →
• high

  FDA accepted BLA for ivonescimab in EGFR-mutated NSCLC with Nov 2026 PDUFA date, but noted statistically significant OS benefit is necessary for approval and PFS results may not be sufficient.

  MD&A: Regulatory verify on EDGAR →
• high

  HARMONi trial showed statistically significant PFS improvement (HR 0.52, p<0.00001) but OS trend missed significance (HR 0.79, p=0.057). China-only HARMONi-A achieved significant OS (HR 0.74, p=0.019).

  MD&A: Clinical Results verify on EDGAR →